Managing Amyloidosis in 2024: Diagnosis and Treatment

Indy Hematology Review

M. Gertz

Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

M. Kwok

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

POEMS Syndrome Management

MyCancerHaven

R. Vij, D. Dingli

Lung Involvement in Amyloidosis

Houston Methodist

H. Huang

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

Updates on AL Amyloidosis Treatment: What’s New in 2024

Dana-Farber Cancer Institute

G. Bianchi

Experts Discuss the Management of Monoclonal Gammopathy of Renal Sig…

MyCancerHaven

R. Vij, N. Leung

Management of AL Amyloidosis

GRACE

S. Rajeeve

Waldenstrom’s Macroglobulinemia: Approaching the Newly Diagnosed and…

Indy Hematology Review

S. Treon

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

Daniel Addison

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

Indy Hematology Review

M. Gertz

"You Have AL-Amyloidosis": Counseling Newly Diagnosed Patients

Morie Gertz

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Diagnosis and Goals of Therapy in PV

Northwestern Medicine Oncology and Hematology

B. Stein

Treating Amyloidosis in 2024

MyCancerHaven

R. Vij, J. Zonder

AL Amyloidosis Treatment Updates

Yale Cancer Center

T. Parker

Experts Discuss Novel Antibodies for the Management of Amyloidosis

MyCancerHaven

R. Vij, S. Lentzsch